We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Selection of Antihypertensive Therapy for Patients With Hypertensive Renal Disease

Vasilios Papademetriou, MD
JAMA. 2001;285(21):2774-2776. doi:10.1001/jama.285.21.2774.
Text Size: A A A
Published online


Hypertension is a major contributor to cardiovascular morbidity and mortality in industrialized countries. During the last 3 decades, multiple prospective randomized trials, reported individually or in meta-analyses,1 demonstrated a dramatic reduction of vascular events attributable to hypertension. At the same time, however, the incidence of end-stage renal disease (ESRD) and congestive heart failure (CHF) has steadily increased.2,3 African Americans are particularly affected by these trends, since they have a higher prevalence and exhibit more severe forms of hypertension, resulting in higher rates of vascular complications. In particular, ESRD attributable to hypertension has increased at a rate that is several-fold higher among African American patients than white patients.4 Although tight blood pressure control is known to be a crucial factor in preventing progression of renal disease, other factors are undoubtedly involved. The potential renal protective effect of specific pharmacologic therapy has been addressed in only a few studies. Recently published reports indicate benefits from angiotensin-converting enzyme inhibitor (ACEI) therapy in patients with diabetes and in those with proteinuria without diabetes,5,6 but these studies included mostly white patients.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles